Boston Scientific Corporation (NYSE:BSX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a moderately bullish view: Boston Scientific has a consensus “Moderate Buy” rating, with 24 buy, five hold and two sell recommendations among 31 brokerages. The average 12-month price target is $71.62.
• Recent results exceeded expectations: Quarterly EPS came in at $0.86 versus the $0.83 consensus, while revenue rose 7.5% year over year to $5.44 billion. The company also authorized a $5 billion share-repurchase program, equivalent to up to 6.4% of outstanding shares.
• Operational risks remain: A cyberattack disrupted shipments, although operations are being restored, and product recalls involving spinal-cord-stimulator leads could increase costs, regulatory scrutiny and liability exposure.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has earned an average rating of "Moderate Buy" from the thirty-one brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-four have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $71.6154.

Several equities research analysts recently commented on BSX shares. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Raymond James Financial reaffirmed an "outperform" rating and issued a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, July 30th. Finally, Mizuho decreased their target price on shares of Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th.

Boston Scientific Trading Up 1.9%

Shares of BSX stock opened at $47.85 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The firm's 50 day moving average price is $46.90 and its two-hundred day moving average price is $55.74. The stock has a market cap of $69.35 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.09 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. The business's quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts anticipate that Boston Scientific will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the business's stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors have recently made changes to their positions in BSX. BlackRock Inc. bought a new stake in shares of Boston Scientific in the second quarter worth $5,534,781,000. California State Teachers Retirement System boosted its stake in Boston Scientific by 4,113.5% during the 2nd quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider's stock valued at $4,136,078,000 after acquiring an additional 94,609,083 shares during the last quarter. Primecap Management Co. CA bought a new position in Boston Scientific during the 2nd quarter valued at $2,156,233,000. Norges Bank acquired a new position in Boston Scientific during the 4th quarter worth $2,199,395,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at about $803,357,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific's ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source